ABSTRACT
INTRODUCTION

Amyotrophic lateral sclerosis (ALS) or motor neuron disease in its purest
A wider range of presentation is recognized, and supported on a pathological and genetic basis. In particular the recognition of cognitive dysfunction, and specifically an association with behavioural variant frontotemporal dementia (FTD).
Despite increasing recognition of genetic and pathological contributions, the details of pathogenesis remain unclear. Disease modifying therapy is limited to riluzole (if nutrition and respiratory support are excluded), and there is no curative treatment. Key overriding considerations in pathogenesis include the contribution of environment and genetics, and the relatively selective vulnerability of motor neurons. The pathogenesis may be conceptualized to have a background vulnerability, a trigger factor, a propagation mechanism, and the final manifestations of the clinical disease ALS. Each of these may involve different factors. This review explores recent evidence adding to our understanding of ALS pathogenesis, but is inevitably not comprehensive, the evidence may be conflicting, and there remains no fully confirmed pathogenic mechanism. The references tend to be reviews, where the prime publications in the field may be obtained, and are not comprehensive. Using statistical modelling, a six step process has been identified as underlying ALS pathogenesis, with conceptual similarities to cancer pathogenesis. 1 The findings at the late stage of disease probably do not represent, and may mask, factors earlier in the disease, which predates onset of any symptoms and signs.
PATHOGENESIS OF ALS
Background vulnerability
Epidemiological studies of ALS show a worldwide incidence of 2-3 per year per 100,000 population over the age of 15 years, and an overall lifetime risk of developing ALS of 1:350 for men and 1:400 for women. Risk increases with age, with a peak around 75 years. 2 Around 10% of individuals have a family history of ALS, and other neurodegenerative conditions including FTD. A study of twin data suggested that heritability contributes 60% to the risk of developing ALS, and environment 40% 3 , but an analysis from three genome-wide association studies found a lower heritability of 21%. 4 Orrell -6 -Genes An increasing number of genes are recognized as associated, and causative of ALS. 5 The most common are C9orf72, SOD1, TARDBP, and FUS. Commonly proposed pathogenic mechanisms include RNA metabolism, and protein metabolism ( Figure 1 , Table 1 ). 6 
C9ORF72
C9orf72 is the most frequent genetic change identified in patients with ALS. It is also specifically found in patients with FTD. Expansions are found in around 39% of familial ALS patients, and 7% of apparently sporadic cases, of European ancestry 7 , but with significant differences between populations. For example, a study of 563 patients with ALS in Japan identified expansions in 0.4% of sporadic and 0% of familial ALS patients 8 , and in less than 1% of Chinese sporadic ALS patients. 9 Patients with ALS often display cognitive changes, and there is an overlap between ALS and FTD. 10 12 The mechanisms of toxicity remain unclear, but a richer understanding is gradually being achieved. 13 
SOD1
Copper zinc superoxide dismutase (SOD1) was the first genetic cause of ALS to be identified, in 1993. 14 Mutations are commonly estimated to be present in around 20% of familial patients, and 1% of apparently sporadic. The frequency will vary between populations, and in an Italian population SOD1 mutations were identified in 14% of familial ALS patients. 15 
Trigger factors
Investigating the earliest stages of ALS in patients is difficult, but pathological studies point to a focal onset, occurring at an apparently random location, and progressing contiguously. 22 This may be an explanation for the range of clinical presentations, i.e. ALS or progressive muscular atrophy (PMA); bulbar or limb onset; ALS or FTD; on the background in some instances of a strong genetic mutation. Inevitably, autopsy data represents the end stage of the disease, and it is difficult to extrapolate to the onset of disease. An alternative theory to contiguous propagation is a network propagation i.e. through axonal and synaptic connections. 23 Protein misfolding and templating of pathogenic proteins, a prion-like mechanism, is currently being explored in ALS and many other neurodegenerative diseases. An EMG approach to determining propagation did not support contiguous spread, and suggested "multifocal hits with local propagation". 24 Imaging studies are becoming increasingly sophisticated. Longitudinal analysis of MRI scans of patients with ALS identified a core white matter pathology -that appeared to be stable -and reflecting upper motor neuron clinical features, but with a progressive grey matter pathology that was widespread, and interpreted as representing a widespread cortical network degeneration. 25 This has implications for developing and monitoring potential therapies.
Epidemiological studies are difficult to perform in ALS, and some results are contradictory. Physical activity, including sports and repeated traumatic events was not found to be a risk factor for ALS, and could be protective. 26 (Figure 2) . 31 
RNA processing
The dominant theory of ALS pathogenesis at present relates to RNA processing.
In particular this is due to the finding of TDP-43 pathology in most ALS cases, and genes including TARDBP and FUS being genetic causes of ALS. These genes are both involved in pre-mRNA splicing, RNA transport and RNA translation. This does not appear to be the case, and oxidative stress is probably a secondary component of pathogenesis.
Mitochondria
Mitochondrial dysfunction is a common feature of many neurodegenerative disorders. There is a body of evidence to support impaired mitochondrial bioenergetics, but also possible roles related to mitophagy and quality control 34 , endoplasmic reticulum stress and calcium signalling. 35 Mutant SOD1 accumulates in the intermembrane space of mitochondria, leading to mitochondrial dysfunction. 36 Mitochondrial dysfunction has been hypothesized to explain a range of clinical features of ALS, including motor neuron hyperexcitability, fasciculations, and differential motor neuron vulnerability. 37 Mutations of the CHCHD10 gene have been identified in patients with ALS.
CHCHD10 is a mitochondrial protein located in the intermembrane space and enriched at cristae junctions. The phenotype of the patients included FTD. 38 Excitotoxicity Glutamate excitotoxicity has long been implicated in ALS pathogenesis. This was supported by neurochemistry studies, and is a potential explanation of selective neuronal vulnerability. This was the basis of trialling riluzole as a treatment for ALS, as a glutamate-release inhibitor. The mechanism of riluzole is unclear, but also has an effect on sodium channels, and calcium-activated potassium channels. 39 
Growth factors
Growth factors are essential in neuronal growth, maintenance and repair. In previous decades there was interest related to their potential therapeutic use, but without success. There is current interest in a Nogo-A monoclonal antibody, to encourage nerve growth. 40 Nogo-A is a neurite outgrowth inhibitor that has been shown to be overexpressed in skeletal muscle in ALS. There are well demonstrated defects of axonal transport in animal models, and human pathological findings of impaired transport. In the majority of patients disturbed axoplasmic flow is probably a secondary, but important, effect.
Templating
The concept of a proteinopathy, or protein-misfolding disorder, is an attractive hypothesis for neurodegenerative disorders, including ALS. 41, 42 Inclusions or misfolded proteins are clearly a common feature of ALS pathology, whatever the genetic or environmental basis. The protein misfolding, and templating, could be an explanation for contiguous propagation. Calling ALS a prion disease has probably confused the issue, and templating may be a preferred term, as this is not proposed to be a prion protein. There is no evidence of infectivity of ALS, although conjugal cases occur rarely. If templating is a propagation mechanism, this should be amenable to potential therapeutic approaches.
Inflammatory
An inflammatory basis to neurodegeneration is well recognised. In ALS there is an understandable focus on the motor neurons, but evidence exists that this is a non-cell-autonomous disease, and non-neuronal cells, in particular microglia may have an important role in pathogenesis. This is a complex area, and much of the data is based on animal models. 43 Nevertheless, inflammatory pathways are a potential therapeutic target, especially in influencing rate of progression. 44 
Myogenic
There has been a long standing debate between the primary neurogenic -and now motor cortex and networks, and the primary myogenic -or neuromuscular junction -origin of ALS. The potential pathogenesis of ALS is, at present broad.
For the patient it is the muscle weakness that causes major disability, and if the muscle weakness could be prevented or reversed, much of the disability would resolve. Muscle weakness unifies the wider presentations of spinal muscular atrophy, spinobulbar muscular atrophy, and the other age-related cachexias.
Growth factors, axonal transport, mitochondrial dysfunction, and other factors impact on this potential cause, contributor or consequence. 45, 46 A number of genes that cause ALS also affect muscle, including VCP, MATR3, and 
CONCLUSION
Therapeutic implications
The lack of a clear pathogenesis has hampered the development of an effective therapy. On the other hand, the abundance of potential mechanisms has led to many attempts at treatments which usually fail in clinical trials. 51 The potential reasons for failure are many, and include the wrong target, inappropriate pharmacodynamics, route of administration, outcome measures, publication bias, and the probability that there may be different pathogenic mechanisms at play in different patients. The genetics of ALS has shown that this represents a plethora of diseases, rather than a single biological entity. The relevance of therapeutic benefit in cell and animal models of ALS remains uncertain. 52, 53 In one individual there may be different mechanisms active at once, or at different stages of the disease. Upstream targets include genetic mechanisms such as SOD1. 21 ALS patients with a range of SOD1 mutations participated in a Phase 1 study of intrathecal antisense oligonucleotide ISIS 333611. 54 There are more than 150 different SOD1 mutations, some family specific. The antisense oligoneucleotide used in this study was designed to activate RNase H mediated degradation of all SOD1, rather than a specific mutant, allowing for a wider potential use, and possibility of an effective clinical trial. C9orf72 creates the potential for a more generic gene therapy. 55 Downstream targets, if identified, allow a more universal therapy, and may be common to other neurodegenerative diseases. ATXN2 (ataxin) remains another potential therapeutic target. 56 
Diagnostic implications
The identification of significant genetic contributions, allows genetic definition of a disease. This has widened our understanding of clinical presentations, including more focal, slowly progressive, and atypical forms, that would not fit classical diagnostic criteria. 
Genetic implications
The identification of genes has the potential for greater understanding of ALS, and prevention or treatment in the future. At present, however, there is uncertainty of the significance of many reported mutations, given the agedependent nature of ALS, the incomplete penetration of causal genes, and varying clinical presentations, including apparently different neurodegenerative diseases with C9orf72. There is much discussion of how best to approach this from a clinical point of view, and there are a range of theories. 57 At one extreme the identification of a gene may be helpful for decision making in families with clear multigeneration autosomal dominant inheritance, such as some families with SOD1 mutations. Given the potential future developments related to our understanding of ALS pathogenesis, genetics, and therapy, there is a strong argument of preserving DNA from affected individuals for future research. Some suggest that all patients with ALS should be tested for all genes and be provided with the relevant information, with appropriate explanation and support. Others suggest that only patients with a clear family history of ALS should be offered the possibility of genetic testing. This is further complicated by the current availability of laboratory testing for genes, and the associated cost. Advances in genetic technology are rapidly solving this issue, with large numbers of genes being sequenced at a relatively low cost. There is a range of clinical views on how to approach this, and a broad view is required. 58 We have achieved the situation where there are a large number of potential genes for ALS, some individuals may have more than one gene, some none, there is variable penetrance, and we do not know how these mutations cause the disease. From being potentially potent in determining outcome, genetic analysis is now but another risk factor -although not to be dismissed. The situation would be transformed if we had preventive or curative approaches based on this knowledge.
Orrell -21 -Orrell -29 - Table 1 Genes implicated in causation of ALS.
(Many of these are very rare causes, and the function given is putative. 5 RNA metabolism 
